BioSpace News Archive

Cambrian BioPharma announced the launch of Amplifier Therapeutics, a biotech focused on developing a clinical-stage AMPK activator.

The life sciences industry saw modest salary growth compared to recent years and gaps persisted for women and racial and ethnic minorities.

The SVB failure appears to have been caused by an underwritten public offering to raise $2.25 billion to cover security losses announced during SVB’s Q1 2023 mid-quarter update.

To hone in on its growth areas, Novartis is looking to trim its ophthalmology portfolio and sell off some of its assets, according to a Bloomberg report published Tuesday.

CytoDyn has spent the past two years under siege. In an exclusive interview, Cyrus Arman, president, told BioSpace how the company is looking to turn the page.

Camber Pharmaceuticals, Inc. is voluntarily recalling lot # E220182 of Atovaquone Oral Suspension, USP 750mg/5mL to the Consumer/User level, due to the potential Bacillus cereus contamination in the product.

Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) (“Miravo” or the “Company”) and Searchlight Pharma Inc., a private Canadian-based specialty healthcare company (“Searchlight”), are pleased to announce the closing of the previously announced plan of arrangement (the “Arrangement”) of Miravo with Searchlight.

Artisan Bio today announced an extension of its research collaboration with Takeda which leverages Artisan’s genome editing technology.

Myosin Therapeutics Inc. announced that it supplemented its National Institutes of Health funding with a seed funding round to advance the company’s lead programs on glioblastoma and stimulant use disorder.

Egg Medical, Inc. is excited to announce that Paul Pharris will be joining the Company as the Chief Revenue Officer and VP of Sales and Business Development.